Iyengar Amit, Hung Matthew L, Asanad Kian, Kwon Oh Jin, Jackson Nicholas J, Reemtsen Brian L, Federman Myke D, Biniwale Reshma M
David Geffen School of Medicine, Ronald Reagan Medical Center, UCLA, Los Angeles, CA, USA.
Department of Cardiothoracic Surgery, Ronald Reagan Medical Center, UCLA, Los Angeles, CA, USA.
Pediatr Cardiol. 2017 Apr;38(4):770-777. doi: 10.1007/s00246-017-1578-9. Epub 2017 Feb 10.
Bleeding and thrombotic events remain a significant cause of morbidity in pediatric patients supported with ventricular assist devices (VADs). The objective of this study is to identify the association between markers of anticoagulation and bleeding and thrombosis events during Berlin Heart ExCor support. A retrospective, single-center analysis of 9 patients supported with the Berlin Heart ExCor was performed. Inflammatory and anticoagulation parameters including C-reactive protein, fibrinogen, partial thromboplastin time (PTT), and platelet count were measured at 48 and 24 h before and after bleeding or thrombosis events. Patients served as their own controls, and the same parameters were measured during a control period where subjects did not experience either event. All patients received the anticoagulation regimen proposed by Berlin Heart. A total of 31 bleeding or thrombotic events were identified and matched to 18 control events. Patient with predominantly thrombotic events tended to weigh less than those with bleeding events (Δ7.7 kg, p < 0.001). PTT levels were higher before and after bleeding (Δ17.36, p = 0.002) and thrombosis (Δ8.75, p < 0.001) events relative to control. Heparin dose decreased after a thrombosis event (Δ-5.67, p = 0.097), and this decrease was significantly different from control (p = 0.032). Non-collinearity between heparin dose and PTT should prompt further inflammatory and hematological investigation. In addition, heavier patients were more prone to bleeding complications. The role of inflammation in the development of thrombus or hemorrhages in the pediatric VAD population needs to be studied further.
在接受心室辅助装置(VAD)支持的儿科患者中,出血和血栓形成事件仍然是发病的重要原因。本研究的目的是确定在柏林心脏ExCor支持期间抗凝标志物与出血和血栓形成事件之间的关联。对9例接受柏林心脏ExCor支持的患者进行了回顾性单中心分析。在出血或血栓形成事件前后48小时和24小时测量炎症和抗凝参数,包括C反应蛋白、纤维蛋白原、部分凝血活酶时间(PTT)和血小板计数。患者作为自身对照,在未发生任何事件的对照期测量相同参数。所有患者均接受柏林心脏提出的抗凝方案。共识别出31例出血或血栓形成事件,并与18例对照事件进行匹配。主要发生血栓形成事件的患者体重往往低于出血事件患者(差异7.7kg,p<0.001)。相对于对照,出血(差异17.36,p=0.002)和血栓形成(差异8.75,p<0.001)事件前后PTT水平更高。血栓形成事件后肝素剂量降低(差异-5.67,p=0.097),且这种降低与对照有显著差异(p=0.032)。肝素剂量与PTT之间的非共线性应促使进一步进行炎症和血液学研究。此外,体重较重的患者更容易出现出血并发症。炎症在儿科VAD人群血栓或出血发生中的作用需要进一步研究。